Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM

CONCLUSIONS
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728. opens in new tab.)

From Research Summary:
LIMITATIONS AND REMAINING QUESTIONS
Further study is required to understand the following:
*Safety and efficacy beyond 2 months and in groups not included in this trial (e.g., children, pregnant women, and immunocompromised persons).
*Whether the vaccine protects against asymptomatic infection and transmission to unvaccinated persons.
*How to deal with those who miss the second vaccine dose.

CONCLUSIONS
Two doses of an mRNA-based vaccine were safe over a median of two months and provided 95% protection against symptomatic Covid-19 in person 16 years of age or older.